{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:29:33Z","timestamp":1789766973573,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014805","name":"Roche SpA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014805","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["25416"],"award-info":[{"award-number":["25416"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["NCT02284581"],"award-info":[{"award-number":["NCT02284581"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.esmoop.2026.108251","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:47:24Z","timestamp":1783442844000},"page":"108251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4231-1184","authenticated-orcid":false,"given":"R.","family":"Caputo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2829-1455","authenticated-orcid":false,"given":"G.","family":"Buono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2417-0589","authenticated-orcid":false,"given":"C.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Botticelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-4333","authenticated-orcid":false,"given":"A.","family":"Caltavituro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pantano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5326-6941","authenticated-orcid":false,"given":"A.","family":"Guarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0416-0292","authenticated-orcid":false,"given":"M.V.","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1131-8690","authenticated-orcid":false,"given":"A.","family":"Diana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Giotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6201-0157","authenticated-orcid":false,"given":"L.","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6813-9426","authenticated-orcid":false,"given":"M.V.","family":"San\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Staropoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6078-4271","authenticated-orcid":false,"given":"C.","family":"Von Arx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pernice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Bajardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7282-3597","authenticated-orcid":false,"given":"G.R.","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Turano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4518-2827","authenticated-orcid":false,"given":"F.B.","family":"Poggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Orditura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4074-2530","authenticated-orcid":false,"given":"G.","family":"Arpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-8033","authenticated-orcid":false,"given":"A.","family":"Fabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1730-3900","authenticated-orcid":false,"given":"M.","family":"Piezzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-5841","authenticated-orcid":false,"given":"L.","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9009-1572","authenticated-orcid":false,"given":"M.","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.108251_bib1","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","article-title":"The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes","volume":"13","author":"Carey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108251_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.esmoop.2026.108251_bib3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/srep00227","article-title":"A gene signature for predicting outcome in patients with basal-like breast cancer","volume":"2","author":"Hallett","year":"2012","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmoop.2026.108251_bib4","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.3390\/curroncol29070378","article-title":"Triple-negative breast cancer: a review of current curative intent therapies","volume":"29","author":"MacDonald","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.esmoop.2026.108251_bib5","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108251_bib6","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108251_bib7","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.2217\/fon-2018-0131","article-title":"Antibody\u2013drug conjugates in triple negative breast cancer","volume":"14","author":"Tray","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.esmoop.2026.108251_bib8","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2026.108251_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920915980","article-title":"Novel antibody\u2013drug conjugates for triple negative breast cancer","volume":"12","author":"Nagayama","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2026.108251_bib10","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14712598.2020.1757067","article-title":"Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy","volume":"20","author":"Goldenberg","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.esmoop.2026.108251_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10549-022-06602-7","article-title":"Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"195","author":"O\u2019Shaughnessy","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2026.108251_bib12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41523-022-00439-5","article-title":"Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer\u2014phase 3 ASCENT study subanalysis","volume":"8","author":"Carey","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.esmoop.2026.108251_bib13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10549-024-07412-9","article-title":"Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States","volume":"208","author":"Kalinsky","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2026.108251_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41523-025-00736-9","article-title":"Real-world outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases","volume":"11","author":"Grinda","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.esmoop.2026.108251_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231200454","article-title":"Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany","volume":"15","author":"Reinisch","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2026.108251_bib16","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s12282-024-01565-7","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases","volume":"31","author":"De Moura","year":"2024","journal-title":"Breast Cancer"},{"key":"10.1016\/j.esmoop.2026.108251_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1362641","article-title":"Sacituzumab govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis","volume":"14","author":"Caputo","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2026.108251_bib18","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/OP.24.00242","article-title":"Real-world clinical outcomes with sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"21","author":"Alaklabi","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.esmoop.2026.108251_bib19","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41416-024-02685-9","article-title":"Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom","volume":"130","author":"Hanna","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2026.108251_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105308","article-title":"Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States","volume":"10","author":"Nanda","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108251_bib21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2217\/fon-2020-0163","article-title":"TROPiCS-02: a phase III study investigating sacituzumab govitecan in the treatment of HR+\/HER2\u2212 metastatic breast cancer","volume":"16","author":"Rugo","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.esmoop.2026.108251_bib22","article-title":"Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial","volume":"86","author":"P\u00e9rez-Garc\u00eda","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.esmoop.2026.108251_bib25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-025-07825-0","article-title":"Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis","volume":"214","author":"Pieni\u0105\u017cek","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2026.108251_bib26","doi-asserted-by":"crossref","first-page":"105828","DOI":"10.1016\/j.esmoop.2025.105828","article-title":"Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer","volume":"10","author":"Morganti","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108251_bib23","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Di Maio","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108251_bib24","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1634\/theoncologist.2019-0647","article-title":"Real-world evidence in oncology: opportunities and limitations","volume":"25","author":"Di Maio","year":"2020","journal-title":"Oncologist"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926021939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926021939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:20:55Z","timestamp":1784546455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926021939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2059702926021939"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108251","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108251"}}